cyclophosphamide

He was diagnosed with Rai Stage I CLL with del6q, without TP53 mutation, and treated with 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) 6 years prior...The patient received three courses of dexamethasone and acyclovir, leading to successful clearance of the infection, evidenced by the resolution of his B symptoms. Subsequently, he was treated for the CLL recurrence with rituximab and venetoclax, demonstrating a favorable response with significant improvement in adenopathy and resolution of lymphocytosis...Timely administration of antiviral therapy is crucial for HSV lymphadenitis to prevent rapid progression and debilitating symptoms. This case demonstrates the importance of considering atypical viral infection presentations in CLL patients and emphasizes the necessity of timely and adequate biopsies to differentiate between CLL transformation, HSV lymphadenopathy, and other causes of lymphadenopathy while avoiding unnecessarily aggressive lymphoma therapy.

The phase 3 PANTHER trial (NCT00798070) compared adjuvant sequential epirubicin/cyclophosphamide (EC) and docetaxel (D) administered in either tailored dose-dense (tDD EC/D) or standard interval schedule (FEC/D) to patients with high-risk resected early breast cancer (n = 2003). We could not reliably identify any subgroup not benefiting from dose-dense treatment, which should be considered for patients with primary resected high-risk breast cancer. Cancerfonden, Bröstcancerförbundet, Radiumhemmets Forskningsfonder, Amgen, Roche, sanofi-aventis.

In addition, pretreatment of CP-administrated mice with RA restored the Nrf2 expression in the liver. Taken together, this study suggests a potential application value of RA in preventing CP hepatotoxicity and sheds light on the possible mechanism.

Our results advocate for the potential of metformin as a viable therapeutic option for preserving ovarian function in cyclophosphamide-treated adolescent girls, given its favorable side effect profile and ability to improve cyclophosphamide-induced ovarian damage.

P2, N=20, Recruiting, Fudan University

P1/2, N=38, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.

P=N/A, N=5, Recruiting, The Alfred- Melbourne | Not yet recruiting --> Recruiting

P3, N=1656, Not yet recruiting, Children's Oncology Group | Initiation date: Dec 2024 --> Mar 2025

P2, N=147, Active, not recruiting, Jules Bordet Institute | Trial primary completion date: Sep 2024 --> May 2025

P3, N=300, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P2, N=100, Recruiting, Fudan University | Not yet recruiting --> Recruiting

P3, N=640, Active, not recruiting, DKMS gemeinnützige GmbH | Recruiting --> Active, not recruiting | Trial completion date: Aug 2026 --> Dec 2026

The dog completed multiple weeks of traditional cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-based treatment and had a survival time of 43 days before the owner elected humane euthanasia. To our knowledge, this report represents a case of acute leukemia in a dog treated with leukoreduction before starting chemotherapy.

Prompt initiation of brentuximab-cyclophosphamide, doxorubicin, and prednisolone therapy ensued. This case underscores the rarity of MPE as an initial presentation of BIA-ALCL and highlights the significance of early recognition and consideration of rare lymphomas in patients with breast implants. Recognize the importance of considering breast implant-associated anaplastic large cell lymphoma in the differential diagnoses of malignant pericardial effusion.

P1/2, N=110, Recruiting, Sotio Biotech Inc. | Trial completion date: Dec 2041 --> Dec 2042 | Trial primary completion date: Apr 2026 --> Oct 2027

P2, N=36, Recruiting, Yale University | Not yet recruiting --> Recruiting

P2, N=30, Not yet recruiting, Sun Yat-sen University

P=N/A, N=230, Not yet recruiting, Peking University People's Hospital

P3, N=360, Not yet recruiting, Immatics US, Inc.

P1, N=50, Enrolling by invitation, Dana-Farber Cancer Institute | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=2017, Active, not recruiting, Karolinska University Hospital | Unknown status --> Active, not recruiting | Trial completion date: Jan 2022 --> Jan 2028

P2, N=41, Active, not recruiting, Jennifer Crombie, MD | Recruiting --> Active, not recruiting

P2, N=30, Not yet recruiting, University of Washington

MTSI involved immunizing BALB/c mice with CFA from Pb18 as a tolerogen and Pl01 as an immunogen, using Freund's adjuvant and cyclophosphamide to induce immune tolerance...The effective generation of P. lutzii-specific antibodies by MTSI demonstrates this technology's promise for the development of accurate PCM diagnostic instruments. These antibodies have the potential to enhance patient outcomes and reduce the incidence of false-negative diagnoses, which could lead to better disease management.

Treatment for the PNET included vincristine, doxorubicin, cyclophosphamide, and ifosfamide/etoposide mesna...The patient also underwent a tandem autologous stem cell transplant with carboplatin/etoposide conditioning and adjuvant etoposide and the subsequent PET/CT scan showed a response to the above treatment...The regimen for our patient yielded promising results. Our aim is to highlight a regimen that can be utilized for this rare aggressive neoplasm.

P2, N=20, Recruiting, Northside Hospital, Inc. | Not yet recruiting --> Recruiting

P=N/A, N=13, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2025 --> Sep 2025

P=N/A, N=50, Recruiting, The University of Hong Kong | Unknown status --> Recruiting | Trial completion date: Jun 2021 --> Dec 2028 | Trial primary completion date: Mar 2021 --> Dec 2028

Procarbazine induces a higher mutation burden and novel mutational signatures in patients with Hodgkin lymphoma treated with eBEACOPP and their germline DNA, raising concerns for the genomic health of survivors of Hodgkin lymphoma and hereditary consequences for their offspring. However, replacing procarbazine with dacarbazine appears to mitigate gonadal and stem-cell toxicity while maintaining similar clinical efficacy.

P2, N=27, Recruiting, University of Illinois at Chicago | Trial completion date: Nov 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Dec 2026

P1/2, N=38, Completed, Prof. Dr. Clemens Schmitt | Active, not recruiting --> Completed | Trial primary completion date: Jun 2024 --> Nov 2024

P1, N=12, Recruiting, Shanghai Cell Therapy Group Co.,Ltd

P1, N=90, Recruiting, Nkarta, Inc.

P2, N=55, Active, not recruiting, Chinese University of Hong Kong | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=20, Not yet recruiting, University of Miami

P1/2, N=1, Terminated, Celularity Incorporated | N=52 --> 1 | Trial completion date: Feb 2025 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Feb 2024; for business reasons

P1/2, N=6, Terminated, ImmunityBio, Inc. | N=80 --> 6 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

P1, N=42, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

P1, N=27, Terminated, Celularity Incorporated | N=94 --> 27 | Recruiting --> Terminated; Business reasons

P1/2, N=74, Active, not recruiting, NYU Langone Health | Recruiting --> Active, not recruiting

P1/2, N=543, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

P1/2, N=2, Terminated, ImmunityBio, Inc. | Phase classification: P1b/2 --> P1/2 | N=332 --> 2 | Active, not recruiting --> Terminated; low enrollment